About AVT
Browse Articles
Authors
Customer Services

Current Issue

Displaying 12 results:

Free
Correction

Correction: Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study

Benoît Trottier, Jordan E Lake, Ken Logue, Cynthia Brinson, Lizette Santiago, Clare Brennan, Justin A Koteff, Brian Wynne, Judy Hopking, Catherine Granier, Michael Aboud

Antiviral Therapy 2017; 22:459-460


Free
Correction

Correction: Safety and efficacy of sofosbuvir plus ledipasvir with and without ribavirin for chronic HCV genotype-1 infection: a systematic review and meta-analysis

Hussien Ahmed, Ahmed Elgebaly, Abdelrahman Ibrahim Abushouk, Ali Mohamed Hammad, Attia Attia, Ahmed Negida

Antiviral Therapy 2017; 22:457


Case report

Elvitegravir/cobicistat-associated toxic optical neuropathy in an HIV-infected patient: a call for caution?

Agostino Riva, Alessandro Invernizzi, Chiara Resnati, Valeria Micheli, Dario Cattaneo, Cristina Gervasoni

Antiviral Therapy 2017; 22:453-455


Short communication

Prevalence of sofosbuvir resistance-associated variants in Brazilian and worldwide NS5B sequences of genotype-1 HCV

Allan Peres-da-Silva, Carlos Eduardo Brandão-Mello, Elisabeth Lampe

Antiviral Therapy 2017; 22:447-451


Short communication

Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate

Nicolas Margot, Stephanie Cox, Moupali Das, Scott McCallister, Michael D Miller, Christian Callebaut

Antiviral Therapy 2017; 22:443-446


Original article

HCV genotype-1 subtypes and resistance-associated substitutions in drug-naive and in direct-acting antiviral treatment failure patients

Yael Gozlan, Ziv Ben-Ari, Roy Moscona, Rachel Shirazi, Aviya Rakovsky, Arij Kabat, Ella Veizman, Tania Berdichevski, Peretz Weiss, Oranit Cohen-Ezra, Yoav Lurie, Inna Gafanovich, Marius Braun, Michal Cohen-Naftaly, Amir Shlomai, Oren Shibolet, Ehud Zigmond, Eli Zuckerman, Michal Carmiel-Haggai, Assy Nimer, Rawi Hazzan, Yaakov Maor, Yona Kitay-Cohen, Yonat Shemer-Avni, Zipi Kra-Oz, Licita Schreiber, Ofer Peleg, Saleta Sierra, P Richard Harrigan, Ella Mendelson, Orna Mor

Antiviral Therapy 2017; 22:431-441


Original article

Association of HIV infection with biomarkers of kidney injury and fibrosis in the Multicenter AIDS Cohort Study

Vasantha Jotwani, Rebecca Scherzer, Michelle M Estrella, Lisa P Jacobson, Mallory D Witt, Frank Palella, Ken Ho, Michael Bennett, Chirag R Parikh, Joachim H Ix, Michael Shlipak

Antiviral Therapy 2017; 22:421-429


Original article

Preclinical characterization of the novel HCV NS3 protease inhibitor GS-9256

Huiling Yang, Chris Yang, Yujin Wang, Gerry Rhodes, Margaret Robinson, Guofeng Cheng, Xiaoping Qi, Hongmei Mo, Yang Tian, Rowchanak Pakdaman, X Christopher Sheng, Choung U Kim, William E Delaney

Antiviral Therapy 2017; 22:413-420


Original article

Increases in CD4+ T-cell count at antiretroviral therapy initiation among HIV-positive illicit drug users during a treatment-as-prevention initiative in Canada

Mimi Tran, Evan Wood, Thomas Kerr, Sophie Patterson, David Bangsberg, Huiru Dong, Silvia Guillemi, Julio SG Montaner, M-J Milloy

Antiviral Therapy 2017; 22:403-411


Original article

Life expectancy after initiation of combination antiretroviral therapy in Thailand

Sirinya Teeraananchai, Suchada Chaivooth, Stephen J Kerr, Sorakij Bhakeecheep, Anchalee Avihingsanon, Achara Teeraratkul, Petchsri Sirinirund, Matthew G Law, Kiat Ruxrungtham

Antiviral Therapy 2017; 22:393-402


Page:
Copyright © Nucleus Global 2017. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.